Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

NCT07160790 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-erosive Gastroesophageal Reflux Disease

Interventions

DRUG: JP-1366 + placebo
DRUG: Placebo + Placebo

Sponsor

Onconic Therapeutics Inc.